Alphamab Oncology jumps on progress of ovarian cancer drug

Alphamab Oncology

18/12/2025 05:37

** Alphamab Oncology 9966.HK rises 7.1% to HK$10.96; set for biggest one-day pct gain since October 2

** Stock hits highest since December 15 after three straight sessions of fall

** Company says its JSKN003 has been granted breakthrough therapy designation (BTD) by U.S. FDA to treat adults with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer

** Adds, "The grant of this BTD further demonstrates the international regulatory community's confidence in JSKN003's clinical potential and its importance as a novel therapeutic candidate"

** Grant of BTD based on pooled analysis of phase I clinical study in Australia and phase I/II clinical study in China

** YTD, stock surges 207.1%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))